The U.S. Food and Drug Administration (FDA) has granted traditional approval to Braftovi (encorafenib) for adult patients ...
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI® (encorafenib) in ...
The BRAFTOVI combination regimen is the only approved targeted regimen for first-line BRAF-V600E mutant metastatic colorectal cancerPivotal results from the Phase 3 portion with mFOLFOX6 of the ...
Phase III data show the Braftovi regimen significantly improves overall survival and response versus chemo as a frontline treatment for advanced tumors.
During a live event, Daniel Olson, MD, discussed data and experience using tumor-infiltrating lymphocytes in melanoma.
Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel immuno-oncology ...
In addition to the presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the ...
Pfizer announces positive results from pivotal BREAKWATER trial of Braftovi in combo with cetuximab & Folfiri in patients with metastatic colorectal cancer: New York Wednesday, Fe ...
Researchers evaluated a different chemo regimen in combination with Braftovi and Erbitux, which is already approved with mFOLFOX6.
"Second Pfizer Braftovi regimen shows benefit in mCRC" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.
BREAKWATER trial Cohort 3 analysis demonstrated statistically significant and clinically meaningful improvement in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results